NCT03719690Phase 2Completed

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Study sponsor: Kura Oncology, Inc. · KURA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-02Actual
Enrollment · participants296Actual
Source updated2024-06-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview